Coherus BioSciences Inc
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · March 31, · · December 31, | ||||||
| · 2025 · 2024 | ||||||
| Assets · · · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $82,411 | | $125,987 | ||
| Trade receivables, net | | | 60,488 | | 111,324 | |
| TSA receivables, net | | | 1,948 | | | 11,010 |
| Inventory | | | 3,518 | | 4,207 | |
| Prepaid manufacturing | | 6,908 | | 6,653 | ||
| Other prepaids and current assets | | | 15,930 | | 10,222 | |
| Assets held for sale, current (Note 6) | | | 138,972 | | | 72,180 |
| Total current assets | | 310,175 | | 341,583 | ||
| Property and equipment, net | | 2,256 | | 2,576 | ||
| Intangible assets, net | | 52,979 | | 53,646 | ||
| Other assets, non-current | | 5,656 | | 6,485 | ||
| Assets held for sale, non-current (Note 6) | | | — | | | 44,243 |
| Total assets | | $371,066 | | $448,533 | ||
| | | | | | | |
| Liabilities and Stockholders’ Deficit | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $40,930 | | $28,456 | ||
| Accrued rebates, fees and reserves | | | 147,738 | | 164,867 | |
| TSA payables and other accrued liabilities | | | 128 | | | 11,026 |
| Accrued compensation | | | 19,950 | | 18,344 | |
| Accrued and other current liabilities | | | 46,296 | | 60,288 | |
| Total current liabilities | | | 255,042 | | 282,981 | |
| Term loan, non-current | | | 36,781 | | | 36,698 |
| Convertible notes | | | 228,569 | | | 228,229 |
| Lease liabilities, non-current | | | 2,854 | | 3,286 | |
| Other liabilities, non-current | | | 31,290 | | 29,329 | |
| Total liabilities | | 554,536 | | 580,523 | ||
| Commitments and contingencies (Note 9) | | | ||||
| Stockholders’ deficit: | | | ||||
| Preferred stock ($0.0001 par value; shares authorized: 5,000,000; shares issued and outstanding: 0 at March 31, 2025 and December 31, 2024) | | | — | | | — |
| Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 115,907,216 and 115,614,548 at March 31, 2025 and December 31, 2024, respectively) | | 12 | | 12 | ||
| Additional paid-in capital | | 1,424,355 | | 1,419,266 | ||
| Accumulated other comprehensive loss | | (275) | | (275) | ||
| Accumulated deficit | | (1,607,562) | | (1,550,993) | ||
| Total stockholders' deficit | | (183,470) | | (131,990) | ||
| Total liabilities and stockholders’ deficit | | $371,066 | | $448,533 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.